Advertisement

Drugs

, Volume 68, Issue 12, pp 1621–1634 | Cite as

Managing the Patient with Co-Morbid Depression and an Anxiety Disorder

  • Robert A. SchoeversEmail author
  • Henricus L. Van
  • Vincent Koppelmans
  • Simone Kool
  • Jack J. Dekker
Therapy in Practice

Abstract

Depression and anxiety disorders frequently co-occur. This type of co-morbidity is associated with higher severity, suicidality, chronicity and treatment resistance. However, available treatment guidelines mainly focus on treatment for singular disorders. The current paper describes diagnostic and treatment issues relevant for adequately addressing patients with depression and an anxiety disorder, using information from both guidelines and a search of recent literature.

Apart from differential diagnosis, the diagnostic evaluation should include a thorough assessment of the symptoms of both disorders, preferably by using a structured clinical interview, and an assessment of depression severity in terms of suicidality, psychotic symptoms and impairment. Treatment should first address the primary disorder in terms of severity and risk. As a rule, severe depression should be treated before the anxiety disorder, using antidepressant medication or combined treatment (plus psychotherapy). In less severe pathology, the primary focus may be determined by examining the temporal pattern and the subjective burden of each disorder as experienced by the patient.

Treatment is often sequential. Treatment of the primary disorder may or may not relieve the co-morbid disorder as well. If the primary disorder is an anxiety disorder, co-morbid depression generally implies earlier use of an antidepressant. Co-morbid mild depression may also react favourably to psychotherapeutic treatment of the anxiety disorder. Recent literature on concurrent treatment of both depression and anxiety shows that modern antidepressants such as sertraline, paroxetine, fluoxetine, venlafaxine, nefazodone and bupropion have demonstrated efficacy in relieving both depressive and anxiety symptoms compared with placebo. Head-to-head comparisons, although relatively scarce, tend to show superiority over tricyclic antidepressants. Venlafaxine was found to be more effective than fluoxetine in some studies. However, these results should be interpreted with caution because studies vary considerably in terms of patient selection, assessment of anxiety and primary outcome measures. Only one randomized controlled trial compared atypical antipsychotics with placebo. Psychotherapy was generally shown to have a beneficial effect on the co-morbid conditions, and available evidence appears to favour combined treatment. The results should be interpreted with caution because the number of studies on this issue was relatively small, with considerable clinical and methodological heterogeneity.

Keywords

Fluoxetine Anxiety Disorder Paroxetine Obsessive Compulsive Disorder Venlafaxine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Drs Schoevers, Van and Dekker report receiving unrestricted educational grants from Wyeth and Eli Lilly. Drs Koppelmans and Kool have no conflicts that are directly relevant to the content of this review.

References

  1. 1.
    Ustun TB, yuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004; 184: 386–92PubMedCrossRefGoogle Scholar
  2. 2.
    Charney DS, Reynolds III CF, Lewis L, et al. Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry 2003; 60(7): 664–72PubMedCrossRefGoogle Scholar
  3. 3.
    Katon WJ, Lin E, Russo J, et al. Increased medical costs of a population-based sample of depressed elderly patients. Arch Gen Psychiatry 2003; 60(9): 897–903PubMedCrossRefGoogle Scholar
  4. 4.
    Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262(7): 914–9PubMedCrossRefGoogle Scholar
  5. 5.
    Kessler RC, Berglund P, Dernier O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289(23): 3095–105PubMedCrossRefGoogle Scholar
  6. 6.
    Katon W, Sullivan MD. Depression and chronic medical illness. J Clin Psychiatry 1990; 51 Suppl.: 3–11PubMedGoogle Scholar
  7. 7.
    Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51(1): 8–19PubMedCrossRefGoogle Scholar
  8. 8.
    Kessler RC, Berglund P, Dernier O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62(6): 593–602PubMedCrossRefGoogle Scholar
  9. 9.
    Weissman MM, Bland R, Joyce PR, et al. Sex differences in rates of depression: cross-national perspectives. J Affect Disord 1993; 29(2-3): 77–84PubMedCrossRefGoogle Scholar
  10. 10.
    Liebowitz MR, Hollander E, Schneier F, et al. Anxiety and depression: discrete diagnostic entities? J Clin Psychopharmacol 1990; 10 (3 Suppl.): 61–6CrossRefGoogle Scholar
  11. 11.
    Tyrer P. Comorbidity or consanguinity. Br J Psychiatry 1996; 168(6): 669–71PubMedCrossRefGoogle Scholar
  12. 12.
    Ball SG, Otto MW, Pollack MH, et al. Predicting prospective episodes of depression in patients with panic disorder: a longitudinal study. J Consult Clin Psychol 1994; 62(2): 359–65PubMedCrossRefGoogle Scholar
  13. 13.
    Wittchen HU, Kessler RC, Pfister H, et al. Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatrica Scandinavica 2000; 406 Suppl.: 14–23PubMedCrossRefGoogle Scholar
  14. 14.
    de Graaf R, Bijl RV, Spijker J, et al. Temporal sequencing of lifetime mood disorders in relation to comorbid anxiety and substance use disorders: findings from the Netherlands Mental Health Survey and Incidence Study. Soc Psychiatry Psychiatr Epidemiol 2003; 38(1): 1–11PubMedCrossRefGoogle Scholar
  15. 15.
    Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry 1996; 30 Suppl.: 17–30Google Scholar
  16. 16.
    Lenze EJ, Mulsant BH, Shear MK, et al. Comorbidity of depression and anxiety disorders in later life. Depress Anxiety 2001; 14(2): 86–93PubMedCrossRefGoogle Scholar
  17. 17.
    Schoevers RA, Deeg DJ, van TW, et al. Depression and generalized anxiety disorder: co-occurrence and longitudinal patterns in elderly patients. Am J Geriatr Psychiatry 2005; 13(1): 31–9PubMedGoogle Scholar
  18. 18.
    Middeldorp CM, Cath DC, Van DR, et al. The co-morbidity of anxiety and depression in the perspective of genetic epidemiology: a review of twin and family studies. Psychol Med 2005; 35(5): 611–24PubMedCrossRefGoogle Scholar
  19. 19.
    Kendler KS. Major depression and generalised anxiety disorder. Same genes, (partly) different environments: revisited. Br J Psychiatry 1996; 30 Suppl.: 68–75Google Scholar
  20. 20.
    Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50(5): 387–93PubMedCrossRefGoogle Scholar
  21. 21.
    Gaynes BN, Magruder KM, Burns BJ, et al. Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression? Gen Hosp Psychiatry 1999; 21(3): 158–67PubMedCrossRefGoogle Scholar
  22. 22.
    Nelson JC. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J Clin Psychiatry 2005; 66(11): 1409–14PubMedCrossRefGoogle Scholar
  23. 23.
    Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 2005; 62(11): 1249–57PubMedCrossRefGoogle Scholar
  24. 24.
    Fava M, Alpert JE, Carmin CN, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004; 34(7): 1299–308PubMedCrossRefGoogle Scholar
  25. 25.
    Multidisciplinaire richtlijn angststoornissen. Landelijke stuurgroep Multidisciplinaire richtlijnontwikkeling in de GGZ [report]. Utrecht: Dutch Institute for Healthcare CBO, the Netherlands Institute of Health and Addiction, 2003Google Scholar
  26. 26.
    Multidisciplinaire richtlijn depressie. Landelijke stuurgroep Multidisciplinaire richtlijnontwikkeling in de GGZ [report]. Utrecht: Dutch Institute for Healthcare CBO, the Netherlands Institute of Health and Addiction, 2005Google Scholar
  27. 27.
    National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Health technology assessment database 2007 (4) [online]. Available from URL: http://www.nice.org.uk/CG023 [Accessed 2008 Jun 23]
  28. 28.
    Mclntosh A, Cohen A, Turnbull N, et al. Clinical guidelines and evidence review for panic disorder and generalised anxiety disorder. Sheffield: University of Sheffield/London, National Collaborating Centre for Primary Care, 2004Google Scholar
  29. 29.
    American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. Am J Psychiatry 1998; 155 (5 Suppl.): 1–34Google Scholar
  30. 30.
    American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157 (4 Suppl.): 45Google Scholar
  31. 31.
    Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6(4): 278–96PubMedCrossRefGoogle Scholar
  32. 32.
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9PubMedCrossRefGoogle Scholar
  33. 33.
    Corruble E, Legrand JM, Duret C, et al. IDS-C and IDS-sr: psychometric properties in depressed in-patients. J Affect Disord 1999; 56(2-3): 95–101PubMedCrossRefGoogle Scholar
  34. 34.
    Rush AJ, Giles DE, Schlesser MA, et al. The inventory for depressive symptomatology (IDS): preliminary findings. Psychiatry Res 1986; 18(1): 65–87PubMedCrossRefGoogle Scholar
  35. 35.
    Rush AJ, Gullion CM, Basco MR, et al. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med 1996; 26(3): 477–86PubMedCrossRefGoogle Scholar
  36. 36.
    Ruhe HG, Dekker JJ, Peen J, et al. Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores. Compr Psychiatry 2005; 46(6): 417–27PubMedCrossRefGoogle Scholar
  37. 37.
    Fava GA. The intellectual crisis of psychiatric research. Psychother Psychosom 2006; 75(4): 202–8PubMedCrossRefGoogle Scholar
  38. 38.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000CrossRefGoogle Scholar
  39. 39.
    World Health Organization. Composite International Diagnostic Interview (CIDI) researcher’s manual. Geneva: World Health Organization; 1994Google Scholar
  40. 40.
    First MB, Gibbon M, Spitzer RL, et al. User’s guide for the SCID-I: structured clinical interview for DSM-IV-TR axis I disorders (research version). New York: New York State Psychiatric Institute, 2002Google Scholar
  41. 41.
    Lecrubier Y, Sheehan DV, Weiller E, et al. The mini international neuropsychiatric interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997; 12(5): 224–31Google Scholar
  42. 42.
    Beurs ED, Beekman ATF, Balkom AJLM, et al. Consequences of anxiety in older persons: its effects on disability, well-being and use of health services. Psychol Med 1999; 29: 583–93PubMedCrossRefGoogle Scholar
  43. 43.
    Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990Google Scholar
  44. 44.
    Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003; 64(2): 161–74PubMedCrossRefGoogle Scholar
  45. 45.
    Kiejna A, Rymaszewska J, Hadry T, et al. Bipolar or unipolar? The question for clinicians and researchers. J Affect Disord 2006; 93(1-3): 177–83PubMedCrossRefGoogle Scholar
  46. 46.
    American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (4 Suppl.): 1–50CrossRefGoogle Scholar
  47. 47.
    Regier DA, Rae DS, Narrow WE, et al. Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry Suppl 1998; (34): 24–8Google Scholar
  48. 48.
    Tasman A, Kay J, Lieberman JA. Psychiatry. 2nd ed. New York: John Wiley & Sons, 2004Google Scholar
  49. 49.
    Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997; 54(11): 1009–15PubMedCrossRefGoogle Scholar
  50. 50.
    Fava GA, Ruini C, Rafanelli C. Sequential treatment of mood and anxiety disorders. J Clin Psychiatry 2005; 66(11): 1392–400PubMedCrossRefGoogle Scholar
  51. 51.
    Koran LM, Hanna GL, Hollander E, et al., American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder [published erratum appears in Am J Psychiatry 2007; 164(8): 1271]. Am J Psychiatry 2007 Jul; 164 (7 Suppl.): 5–53CrossRefGoogle Scholar
  52. 52.
    American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington (VA): American Psychiatric Association, 2007 [online]. Available from URL: http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm [Accessed 2008 Jun 23]
  53. 53.
    Ursano RJ, Bell C, Eth S, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry 2004; 161 (11 Suppl.): 31Google Scholar
  54. 54.
    Bisson JI, Ehlers A, Matthews R, et al. Psychological treatments for chronic post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry 2007; 190: 97–104PubMedCrossRefGoogle Scholar
  55. 55.
    Servan-Schreiber D, Schooler J, Dew MA, et al. Eye movement desensitization and reprocessing for posttraumatic stress disorder: a pilot blinded, randomized study of stimulation type. Psychother Psychosom 2006; 75(5): 290–7PubMedCrossRefGoogle Scholar
  56. 56.
    Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994; 55(2): 50–9PubMedGoogle Scholar
  57. 57.
    Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995; 56 Suppl. 6: 37–42PubMedGoogle Scholar
  58. 58.
    Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 1998; 18(2): 136–44PubMedCrossRefGoogle Scholar
  59. 59.
    Fava M, Rosenbaum JF, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000; 59(2): 119–26PubMedCrossRefGoogle Scholar
  60. 60.
    Frank E, Shear MK, Rucci P, et al. Influence of panic-agoraphobic spectrum symptoms on treatment response in patients with recurrent major depression. Am J Psychiatry 2000; 157(7): 1101–7PubMedCrossRefGoogle Scholar
  61. 61.
    Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsycho-pharmacology 2001; 25(1): 131–8CrossRefGoogle Scholar
  62. 62.
    Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001; 62(7): 523–9PubMedCrossRefGoogle Scholar
  63. 63.
    Lipman R, Covi L. Outpatient treatment for neurotic depression: medication and group psychotherapy. In: Spitzer RL, Klein DL, editors. Evaluation of the psychological therapies. Baltimore (MD): John Hopkins University Press, 1976Google Scholar
  64. 64.
    Lenze EJ, Mulsant BH, Dew MA, et al. Good treatment outcomes in late-life depression with comorbid anxiety. J Affect Disord 2003 Dec; 77(3): 247–54PubMedCrossRefGoogle Scholar
  65. 65.
    Altamura AC, Montresor C, Salvadori D, et al. Does comorbid subthreshold anxiety affect clinical presentation and treatment response in depression? A preliminary 12-month naturalistic study. Int J Neuropsychopharmacology 2004; 7(4): 481–7CrossRefGoogle Scholar
  66. 66.
    Misri S, Reebye P, Corral M, et al. The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. J Clin Psychiatry 2004; 65(9): 1236–41PubMedCrossRefGoogle Scholar
  67. 67.
    Hegel MT, Unutzer J, Tang L, et al. Impact of comorbid panic and posttraumatic stress disorder on outcomes of collaborative care for late-life depression in primary care. Am J Geriatr Psychiatry 2005; 13(1): 48–58PubMedGoogle Scholar
  68. 68.
    Ledley DR, Huppert JD, Foa EB, et al. Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depress Anxiety 2005; 22(4): 161–7PubMedCrossRefGoogle Scholar
  69. 69.
    Mclntyre A, Gendron A, Mclntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007; 24(7): 487–94CrossRefGoogle Scholar
  70. 70.
    Young JF, Mufson L, Davies M. Impact of comorbid anxiety in an effectiveness study of interpersonal psychotherapy for depressed adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45(8): 904–12PubMedCrossRefGoogle Scholar
  71. 71.
    Andreescu C, Lenze EJ, Dew MA, et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry 2007; 190: 344–9PubMedCrossRefGoogle Scholar
  72. 72.
    Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005; 66 Suppl. 8: 22–9PubMedCrossRefGoogle Scholar
  73. 73.
    de Maat SM, Dekker JJ, Schoevers RA, et al. Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: a mega-analysis based on three randomized clinical trials. Depress Anxiety. Epub 2007 Jun 7Google Scholar
  74. 74.
    de Maat SM, Dekker JJ, Schoevers RA, et al. Relative efficacy of psychotherapy and combined therapy in the treatment of depression: a meta-analysis. Eur Psychiatry 2007; 22(1): 1–8PubMedCrossRefGoogle Scholar
  75. 75.
    Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342(20): 1462–70PubMedCrossRefGoogle Scholar
  76. 76.
    Widiger TA, Simonsen E, Krueger R, et al. Personality disorder research agenda for the DSM-V. J Personal Disord 2005; 19(3): 315–38CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Robert A. Schoevers
    • 1
    • 2
    Email author
  • Henricus L. Van
    • 1
  • Vincent Koppelmans
    • 1
  • Simone Kool
    • 1
  • Jack J. Dekker
    • 1
    • 3
  1. 1.JellinekMentrum Mental Health Care AmsterdamAmsterdamthe Netherlands
  2. 2.Department of Psychiatry, Medical CenterVU UniversityAmsterdamthe Netherlands
  3. 3.Department of Clinical PsychologyVU UniversityAmsterdamthe Netherlands

Personalised recommendations